Aimed Op-Ed Featured in The Hill: “Congress: Keep the Nation’s Drug Safety System Intact”
The Hill has published an op-ed by Aimed Alliance’s Director of Public Policy, Stacey L.…
Browsing: FDA
New Aimed Alliance Article, Published in Journal of Pharmaceutical Policy and Practice, Calls for Preservation of REMS Program
Aimed Alliances Urges Congress to Keep the Current Risk Evaluation and Mitigation Strategies (REMS) Program Intact…
Aimed Alliance Testifies at FDA Committee Hearing on Novel New Drug
Aimed Alliance’s Director of Medical Affairs, Dr. Shannon Ginnan, testified on an innovative buprenorphine subdermal…
Aimed Alliance Submits Comment to FDA on Approval of Generic Chronic Dry Eye Med
Earlier today, Aimed Alliance’s Director of Public Policy, Stacey L. Worthy, submitted a comment to…
Aimed Alliance Presents Testimony Urging FDA Panel’s Approval of Novel Treatment
Today, Aimed Alliance presented testimony before a joint meeting of the U.S. Food and Drug…
FDA Releases Much-Anticipated Guidelines on Biosimilar Naming
This week, the U.S. Food and Drug Administration (FDA) released its much-anticipated guidelines on the…
Aimed Alliance Signs on to 21st Century Cures Letter
Today, the National Health Council sent a letter signed by Aimed Alliance and 250 other…
FDA Releases Three Final Guidances on Biosimilars
The U.S. Food and Drug Administration (FDA) has issued three final guidances on biosimilars, which…
Aimed Alliance Participates in CBI’s Q&A
In preparation for CBI’s Abuse Deterrent Formulations Summit, at which Aimed Alliance’s Director of Public…